Fig. 6: Drug screening and validation based on FeSig. | Communications Biology

Fig. 6: Drug screening and validation based on FeSig.

From: Ferroptosis-related gene signature for predicting prognosis and identifying potential therapeutic drug in EGFR wild-type lung adenocarcinoma

Fig. 6

a Correlation analysis of FeSig score and drug IC50 concentration from NCI-60 dataset. b Drug screening combining connectivity map dataset and sensitive drug screened from 6a. c Clone formation assay of H3122 and A549 under 0 mM, 0.5 mM and 1 mM 6-MP. d Quantitative analysis of clone formation assay in 6c (Student’s t test, two tailed). e Representative pictures of H3122 and A549 subcutaneous tumor with PBS control or 6-MP treatment. f Quantitative analysis of control tumor wight and 6-MP treated tumor wight of H3122 and A549, respectively. g IHC of α-SMA in control and 6-MP treated H3122 and A549 subcutaneous tumors. Scale bar: 100μm. h Relative fold change of decreased α-SMA area in 6-MP treated H3122 and A549 subcutaneous tumors. Error bars depict as mean ± SD.

Back to article page